Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) traded up 1.5% during mid-day trading on Tuesday . The stock traded as high as $2.71 and last traded at $2.66. 144,413 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 151,846 shares. The stock had previously closed at $2.62.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Wall Street Zen raised shares of Immix Biopharma to a "hold" rating in a research note on Friday, June 27th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Wednesday, June 4th.
Read Our Latest Report on IMMX
Immix Biopharma Stock Down 1.9%
The company's 50 day moving average price is $2.24 and its two-hundred day moving average price is $1.99. The stock has a market cap of $75.25 million, a P/E ratio of -3.86 and a beta of 0.24.
Hedge Funds Weigh In On Immix Biopharma
A hedge fund recently bought a new stake in Immix Biopharma stock. SBI Securities Co. Ltd. purchased a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned about 0.06% of Immix Biopharma at the end of the most recent quarter. 11.26% of the stock is owned by institutional investors.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
